Chief Scientific Officer Vinayak Doraiswamy filed a Form 4 with the Securities and Exchange Commission disclosing the sale of 5,000 shares of AtriCure Inc. (NASDAQ: ATRC) common stock on March 12, 2026. The shares traded within a range of $29.79 to $29.92 per share. The weighted average price for the sale was $29.83, producing total proceeds of $149,150.
The transaction occurred while AtriCure's shares were trading near a 52-week low of $28.29 and the stock was down 24.6% year-to-date. Following the disposition, Doraiswamy is recorded as directly holding 96,875 shares of AtriCure.
Independent analysis highlighted in the filing notes from InvestingPro indicates that the stock may be undervalued at current market levels, with some analyst price targets reaching as high as $55. The InvestingPro commentary also notes that net income is expected to grow this year, and that there are 8 additional InvestingPro Tips available for ATRC subscribers.
Earlier corporate disclosures show AtriCure beat expectations for the fourth quarter of 2025. The company reported adjusted earnings per share of $0.06, compared with a consensus estimate of -$0.10. Revenue for the quarter came in at $140.5 million, slightly above the $139.55 million analysts had forecast, representing a 13.1% increase year-over-year.
Brokerage reactions to the quarterly results were mixed. Oppenheimer downgraded AtriCure from Outperform to Perform, citing competitive concerns, and removed its $44 price target. Canaccord Genuity lowered its price target to $53 from $64 while retaining a Buy rating, attributing the change to valuation compression. Citizens trimmed its target to $52 from $60 and kept a Market Outperform rating, noting potential future opportunities. Needham reiterated a Buy rating and maintained a $45 price target, emphasizing that AtriCure’s adjusted EBITDA and earnings per share exceeded consensus estimates.
Despite the range of analyst moves, the company said it is holding its revenue and adjusted EBITDA guidance for 2026 and issued EPS guidance that is above consensus.
Summary of the insider sale, recent financial performance, and analyst reactions is presented above. The sale, occurring amid a down year-to-date stock price and close to the 52-week low, comes after a quarter where AtriCure topped consensus on both adjusted EPS and revenue, and precedes several broker adjustments to price targets and ratings.
The facts reported here derive from the Form 4 filing and the company's published quarterly results and subsequent analyst commentary.